FDA Approves First-of-Its-Kind Device for Locally Advanced Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved Optune Pax®, a first-of-its-kind, non-invasive device developed by Novocure, for the treatment of adult patients with locally advanced pancreatic cancer. This approval marks a significant advancement in pancreatic cancer treatment, offering a new therapeutic option for a disease with limited effective treatments.
How Optune Pax Works
Optune Pax delivers Tumor Treating Fields (TTFields) – alternating electrical fields – to the abdomen via portable, wearable adhesive patches connected to an electric field generator. TTFields disrupt cancer cell division, hindering the rapid growth characteristic of pancreatic cancer, while aiming to minimize harm to healthy tissue. The device’s treatment parameters are pre-set by the manufacturer, ensuring consistent and controlled delivery of TTFields.
Clinical Trial Results: The PANOVA-3 Trial
The FDA’s approval is based on data from the pivotal Phase 3 PANOVA-3 clinical trial. In this trial, patients with locally advanced pancreatic cancer were treated with standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) either alone or in combination with TTFields. Results demonstrated that adding Optune Pax to chemotherapy led to a statistically significant improvement in overall survival, extending it by approximately two months. The treatment significantly extended the time to pain progression, contributing to a better quality of life for patients.
Safety and Side Effects
The most common side effects associated with Optune Pax were localized skin reactions at the site of the adhesive patches. The trial data indicated that TTFields did not add to the systemic side effects typically experienced with chemotherapy.
Expert Perspectives
“In the Phase III PANOVA-3 trial, treatment with Optune Pax resulted in a statistically significant improvement in overall survival without adding to the systemic side effects commonly associated with existing therapies,” said Vincent Picozzi, M.D., MMM, a medical oncologist and investigator in the PANOVA-3 trial. “It also significantly extended time to pain progression, helping to preserve overall quality of life, which is a priority when I am treating patients living with pancreatic cancer.”
FDA Commissioner Marty Makary, M.D., M.P.H., emphasized the importance of this approval, stating, “Having treated many patients with pancreatic cancer, I know how hard the diagnosis can be. The pancreatic cancer community deserves better therapeutic options.”
Pancreatic Cancer Statistics
According to the National Cancer Institute, in 2025, pancreatic cancer was expected to result in approximately 67,440 new diagnoses and 51,980 deaths in the U.S.
Looking Ahead
The approval of Optune Pax represents a significant step forward in the treatment of locally advanced pancreatic cancer, offering a novel, non-invasive option that can be integrated into patients’ daily lives. The FDA’s approval aligns with its Home as a Health Care Hub Initiative, promoting innovative, patient-centered devices that expand access to care beyond traditional clinical settings.